News more

  • Foley Hoag Economic Crisis TeamNow’s the Time:
    Foley Hoag Forms Economic Crisis Team  [Read More]
  • Foley Hoag Congratulates Advanced Electron Beams for Next Round of Financing  [Read More]
  • Human Rights Campaign Releases Corporate Equality Index, Names Foley Hoag Among Top Firms for Second Consecutive Year  [Read More]
  • Foley Hoag Representing Republic of Georgia in Emergency Hearing at International Court of Justice in September; Georgia Claims Violent Ethnic Cleansing by Russia and Its Militia Allies  [Read More]
  • The Vault Recognizes Foley Hoag for Diversity: Ranked a Top 10 Firm for Gays & Lesbians and Ranked in Top 20 for other Diversity Categories  [Read More]

Publications more

  • EEC Perspectives - September 2008 [Read More]
  • Massachusetts Determination of Need Process Expanded to Include New Green Building Standards [Read More]
  • Massachusetts Issues New Regulations Regarding the Fair Share Contribution under the Health Care Reform Law [Read More]
  • Economic Crisis Team Datasheet [Read More]
  • Foley Hoag eBook: Doing Business in the United States [Read More]
  • Medicare Datasheet [Read More]

Events more

October 14, 2008 TCN Breakfast Roundtable: Building a High Growth Business for Angel and Venture Capital [Read More] Emerging Enterprise Center at Foley Hoag
Waltham, MA
October 14, 2008 Clean Energy Transporation Forum [Read More] Emerging Enterprise Center at Foley Hoag
Waltham, MA
October 16, 2008 Personalized Medicine Coalition [Read More] The Ohio State University Medical Center
Columbus, Ohio
October 17, 2008 Computing in the Clouds [Read More] Emerging Enterprise Center at Foley Hoag
Waltham, MA
October 19, 2008 ACC Annual Meeting '08 [Read More] Washington State Convention & Trade Center
Seattle, WA

Client Successes

  • Biomedical Advanced Research and Development Authority (BARDA)
    In a move that created enormous opportunities for early-stage life sciences companies, last year the U.S. Congress revitalized the federal government’s program supporting the development of medical countermeasures critical to protecting the nation against bioterrorism and pandemic threats. The resulting legislation created an agency within the Department of Health and Human Services (HHS), the Biomedical Advanced Research and Development Authority (BARDA). BARDA will inject more than $1 billion into research, development, and procurement of vaccines, antivirals and diagnostics. BARDA enhances coordination between government and emerging companies through support of advanced research and development, the vital phase that occurs in between basic research and commercialization. On behalf of the venture capital firm, Kleiner Perkins Caulfield & Byers, Foley Hoag worked with the HHS, Congressional members, and staff to craft legislation strengthening the nation’s response to pandemic outbreaks and bioterrorism. The key financing aspect of the legislation provides much-needed funding to allow early stage companies to traverse the “valley of death” before product commercialization. The legislation authorizes the Secretary of HHS to expedite contracts and grants, and the Director of BARDA to identify areas of unmet need, spurring further innovation and investment. BARDA institutionalizes the important partnership between the federal government and the life sciences industry, critical to safety, innovation and economic vitality. [Read More]
  • HyperBranch Medical Technology, Inc.
    For our client HyperBranch Medical Technology, Inc., a leader in the field of polymeric medical sealants, we assisted with the intellectual property portfolio strategy in connection with obtaining CE Mark designation for the company’s OcuSeal product. OcuSeal is a liquid ocular bandage used to stabilize ocular wounds following surgical or non-surgical trauma. CE Marking denotes that a product complies with all requirements of European health, safety, and environmental product legislation, and is an important step in bringing products to market overseas. HyperBranch began its research in 2004 with the objective to develop strong enough polymer sealants to ultimately replace sutures that would be easy to use, and would not interfere with natural healing. The Durham, North Carolina medical device company has also, been developing advanced surgical sealants for dura (brain), pleural (lung) and hernia mesh fixation. These products are all at various stages of clinical and pre-clinical development. Read more about HyperBranch Medical Technology here. [Read More]

Blog more